Boundless BioBOLD
Market Cap: $69.7M
About: Boundless Bio Inc is a clinical-stage oncology company. It is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the significant unmet need in patients with oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in more than 14% of cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.
Employees: 72
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
61.66% more ownership
Funds ownership: 0% [Q1] → 61.66% (+61.66%) [Q2]
57% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 7
22% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 18
10% more funds holding
Funds holding: 42 [Q1] → 46 (+4) [Q2]
28% less capital invested
Capital invested by funds: $208M [Q1] → $150M (-$58.1M) [Q2]
100% less funds holding in top 10
Funds holding in top 10: 1 [Q1] → 0 (-1) [Q2]
Research analyst outlook
We haven’t received any recent analyst ratings for BOLD.